US Food and Drug Administration
US Food and Drug Administration
Vepdegestrant’s May 1 approval for ESR1-mutant advanced breast cancer marks the first PROTAC-class drug cleared by the FDA, with VERITAC-2 trial data showing a hazard ratio of 0.70 over fulvestrant.
You must be logged in to post a comment.